

AWARD NUMBER: W81XWH-13-1-0208

TITLE: Regulation of Glucose Utilization by Estradiol in Breast Cancer

PRINCIPAL INVESTIGATOR: Yoannis Imbert-Fernandez

CONTRACTING ORGANIZATION: University of Louisville  
Louisville, KY 40208

REPORT DATE: October 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE October 2014		2. REPORT TYPE ANNUAL REPORT		3. DATES COVERED 30 Sep 2013 - 29 Sep 2014	
4. TITLE AND SUBTITLE Regulation of Glucose Utilization by Estradiol in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0208	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) YOANNIS IMBERT-FERNANDEZ  E-Mail: yimire01@louisville.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UNIVERSITY OF LOUISVILLE 2301 S 3 <sup>RD</sup> ST LOUISVILLE KY 40208-1838				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Administration of estradiol (E2) to estrogen receptor-positive (ER+) breast cancer patients increases glucose uptake by tumors. Accordingly, downstream metabolic regulators of E2 are expected to have utility as targets for the development of anti-breast cancer agents. The family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4) control glycolytic flux via their product, fructose-2,6-bisphosphate (F26BP), which activates 6-phosphofructo-1-kinase (PFK-1). The goal of the proposal was to study a novel regulatory pathway for E2 induced metabolism via PFKFB3 in breast cancer cells. In the initial proposal demonstrate that exposure of human MCF-7 breast cancer cells to E2 causes a rapid increase in glucose uptake that is coincident with an induction of PFKFB3 mRNA, protein expression and the intracellular concentration of its product, F26BP. To this end, we have expanded our studies to include two additional breast cancer cell lines, T47 (ER+) and MDA-MB-231 (ER-) cells. We determined that ER $\alpha$ directly regulates PFKFB3 expression via binding to its promoter. We examined the changes in glucose flux upon E2 administration in a PFKFB3 null and overexpression background and confirmed that E2 increases glucose uptake and glycolysis via PFKFB3. The results from our studies were published in the Journal of Biological Chemistry (see appendix 1).					
15. SUBJECT TERMS Estradiol, Glycolysis, Estrogen receptor, PFKFB3, Cancer metabolism					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  Unclassified	18. NUMBER OF PAGES  20	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  Unclassified	b. ABSTRACT  Unclassified	c. THIS PAGE  Unclassified			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>4</b>
<b>2. Keywords.....</b>	<b>4</b>
<b>3. Accomplishments.....</b>	<b>5</b>
<b>4. Impact.....</b>	<b>8</b>
<b>5. Changes/Problems.....</b>	<b>9</b>
<b>6. Products.....</b>	<b>9</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>10</b>
<b>8. Special Reporting Requirements.....</b>	<b>10</b>
<b>9. Appendices.....</b>	<b>10</b>

## **1. INTRODUCTION**

Glucose uptake by estrogen receptor-positive (ER+) breast cancer tumors is increased upon administration of estradiol (E2). Furthermore, this E2-induced metabolic flare is predictive of the clinical responsiveness to standard anti-estrogen therapies, indicating that glucose metabolism is an important target of the E2-induced response. Given the role of phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in controlling glycolytic flux via activation of 6-phosphofructo-1-kinase (PFK-1), we anticipated that E2 might promote PFKFB3 expression, resulting in increased glucose flux. The central hypothesis of this project is that PFKFB3 is an essential downstream effector of E2 that serves to activate the energetic and anabolic pathways that are required for the survival and growth of breast cancer cells. The purpose of our research is to elucidate the mechanisms for E2-mediated activation of glycolysis in breast adenocarcinoma cells and to examine the effects of combined ER/PFKFB3 targeted therapies on the glucose metabolism and growth of ER+ breast xenographs and spontaneous breast adenocarcinomas in vivo. Here, we describe the tasks that encompass the grant and the progress that has been made.

## **2. KEYWORDS**

Estrogen receptor, Estradiol, PFKFB3, Glucose metabolism, Breast Cancer, Fulvestrant

### 3. ACCOMPLISHMENTS


#### SPECIFIC AIM 1 TASKS

- Task 1 (Months 1-36).** Expand preliminary results to additional breast cell lines. The studies include treating T-47D, ZR-75-1, MDA-MB231 and normal mammary epithelial cells with estradiol and conducting various cell assays to determine PFKFB3 mRNA/protein, F2,6BP, glucose uptake +/- PFKFB3 siRNA or PFK158.  
*50% completed*
- Task 2 (Months 6-12).** ChIP and Luciferase assays.  
*50% completed (Results shown in Appendix 1)*
- Task 3 (Months 9-15).** Conduct metabolomic analyses of extracted cell lysates by capturing NMR spectra at 14.1 T on Varian Inova NMR spectrometer.  
*10% completed*
- Task 4 (Months 10-16).** Measurement of PFK-1 and Hexokinase activity in cells treated with estradiol +/-PFKFB3 siRNA or PFK158.  
*20% completed*


The experiments outlined in Specific Aim 1 seek to understand the mechanisms by which E2 activates glycolysis. Specifically, we focus on the role of PFKFB3 as a downstream target of E2 and activator of glycolysis. Major findings from this aim are described in Imbert-Fernandez, Y., Clem, B.F., O'Neal, J., Kerr, D.A., Spaulding, R., Lanceta, L., Clem, A.L., Telang, S., Chesney J. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). JBC. 2014 Mar 28;289(13)9440-8. PMID:24515104 (Appendix 1). Key results described in the peer-reviewed research article are: 1) PFKFB3 protein is expressed at higher levels in stage II ER+ breast adenocarcinomas relative to normal breast tissues using immunohistochemistry (IHC); 2) PFKFB3 protein, F2,6BP, glucose uptake and glycolysis are induced by E2 in MCF-7 and T47-D cells; ER $\alpha$  is recruited to the promoter of the *pfkfb3* gene upon E2 stimulation (Task 2); 3) E2 increases glucose uptake and glycolysis via PFKFB3 in MCF-7 cells; 4) forced expression of PFKFB3 increases F2,6BP, glucose uptake and glycolysis in MCF-7 cells; 5) ICI 182,780 and PFK158 synergistically induce apoptotic death. Notably, the

studies presented in Appendix 1 include additional studies that were not described in our original research proposal but considerably strengthen our study. For example, we have now incorporated glycolysis measurements in addition to our glucose uptake because it allows us to measure the flux through the glycolysis pathway. Likewise, we performed PFKFB3 overexpression to characterize the requirement of PFKFB3 for the E2-induced increase in glycolysis in addition to PFKFB3 siRNA studies.

We are currently expanding our studies to include T47D (ER+) and MDA-MB231 (ER-) cells. We examined endogenous PFKFB3 protein expression in response to E2 in T47D cells and found that PFKFB3 protein significantly increased after 3h of exposure to 10 nM E2 similarly to our MCF-7 studies (Figure 1). F2,6BP measurement in T47D cells is currently underway. Next, we determined the effects of E2 on PFKFB3 mRNA, protein and F2,6BP in ER- MDA-MB-231 cells. Given that MDA-MB-231 cells are ER-, we transiently transfected a wild type form of ER $\alpha$  for 24 hours followed by E2 stimulation. Surprisingly, there was no change in PFKFB3 mRNA, PKFFB3 protein or F2,6BP in cells expressing either the pCDNA3 empty vector control (EV) or wild type ER $\alpha$  after treatment with 10nM E2 for 1 and 3 hours (Figure 2). We expected to see an increase in PFKFB3 expression and F2,6BP levels in cells expressing the ER $\alpha$  construct but not in the EV. The lack of ER-mediated response in ER transfected cells could be due to a timing issue since we confirmed ER $\alpha$  expression by real-time PCR and western blot (data not shown). To address this issue, additional stimulation times with E2 will be included in subsequent experiments.



**Figure 1. Regulation of PFKFB3 by E2 in T47D cells.** T47D cells were stimulated with 10 nM E2 for 3 hours and analyzed for PFKFB3 protein by western blot. PFKFB3 antibody was from ProteinTech and beta-actin was from Sigma. Shown is a representative western blot, n=3.



**Figure 2. Regulation of PFKFB3 by E2 in MDA-MB-231 cells.** MDA-MB-231 cells were transfected with either pCDNA3 empty vector control (EV) or pCDNA-HA-ER-WT (ER-WT) plasmid 49498 purchased from Addgene. Twenty-four hours after transfection cells were stimulated with 10 nM E2 for 1 hour (RNA) or 3 hours (PFKFB3 protein and F2,6BP) and analyzed for PFKFB3 mRNA (A), PFKFB3 protein by western blot (B) and F2,6BP levels (C). PFKFB3 antibody was from ProteinTech and beta-actin was from Sigma. n=1

Overall, we are making progress in expanding our study in the various cell lines proposed on *Task 1*. We have already completed the ChIP studies proposed on *Task 2* and have acquired the plasmids for the Luciferase assay studies. Regarding *Tasks 3* and *4*, due to the requirement for increased number of cells for the experiments outlines, we have begun developing the procedures necessities to determine optimal cell density and transfection conditions.

## SPECIFIC AIM 2 TASKS

### Task 7 (Months 6-12).

Interbreed Stat1<sup>-/-</sup> mice. The goal is to obtain at minimum of 40 Stat1<sup>-/-</sup> animals to perform the experiments described in Aim 2.

0% completed

We have not initiated our mice studies because we have given priority to our cell line experiments. Our goal is to gain valuable insight into the mechanism regulating PFKFB3 expression by E2 in order to guide our efforts and maximize the outcome from our mouse model studies.

## TRAINING AND PROFESSIONAL DEVELOPMENT

During the first training year, I have consistently attended different professional venues

that are geared towards breast cancer, cancer metabolism and/or gene regulation. These include: 1) Weekly cancer colloquia series, 2) Monthly translational ground rounds series and 3) Monthly Hematology/Oncology journal club. Our 14<sup>th</sup> Annual Brown Center Retreat took place on October 17 and provided an excellent opportunity to discuss relevant research topics among fellow trainees and experts in the cancer field.

## **OUTREACH/DISSEMINATION OF RESULTS**

Recently, we met with a non-profit organization that focuses on Metastatic Breast cancer called Twisted Pink. During our meeting, Twisted pink learnt about PFKFB3 and its regulation by ER, as well as, the research funded by this award. Importantly, we discussed the potential benefits of our discoveries for breast cancer patients. As a result, an article in the local newspaper was published (link below).

<http://www.voice-tribune.com/news/cover-story/twisting-the-perspective-on-cancer/>

To learn about Twisted Pink:

<http://www.twistedpink.org/home.html>

## **FUTURE PLANS FOR THE NEXT REPORTING PERIOD**

Our goal is to continue to make adequate progress on the remaining Specific Aim 1 tasks. In addition, we will submit the necessary animal use documents for approval relating to animal studies in order to initiate the studies proposed in Aim 2.

## **4. IMPACT**

### **IMPACT ON THE PRINCIPAL DISCIPLINE**

Imbert-Fernandez *et. al.* reported the discovery that a key regulator of glycolysis, 6-phosphofructo-2-kinase (PFKFB3), is directly regulated by the estrogen-activated estrogen receptor in breast cancer cells. We also demonstrate that PFKFB3 is required for the stimulatory effect of estradiol on glucose uptake by breast cancer cells and that the combination of an estrogen antagonist and a PFKFB3 inhibitor currently in phase I



trials causes a synergistic increase in apoptosis. We believe that this article will be of significant interest to the scientific community given the recent surge in the development of cancer therapeutics that suppress the metabolism of breast cancer cells.

#### **IMPACT ON OTHER DISCIPLINES**

“Nothing to report”

#### **IMPACT ON TECHNOLOGY TRANSFER**

“Nothing to report”

#### **IMPACT ON SOCIETY BEYOND SCIENCE AND TECHNOLOGY**

We believe our findings provide the foundation for initiating combinatorial studies targeting PFKFB3 and ER simultaneously *in vivo*. The long-term impact of this proposal is that it may enable the combination of PFKFB3 inhibitors and anti-ER in breast cancer patients.

#### **5. CHANGES/PROBLEMS**

“Nothing to report”

#### **6. PRODUCTS**

##### **PUBLICATIONS, CONFERENCE PAPERS, AND PRESENTATIONS**

- **Imbert-Fernandez, Y.**, Clem, B.F., O’Neal, J., Kerr, D.A., Spaulding, R., Lanceta, L., Clem, A.L., Telang, S., Chesney J. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). JBC. 2014 Mar 28;289(13)9440-8. PMID:24515104

##### **WEBSITE(S) OR OTHER INTERNET SITE(S)**

“Nothing to report”

##### **TECHNOLOGIES OR TECHNIQUES**

“Nothing to report”

##### **INVENTIONS, PATENT APPLICATIONS, AND/OR LICENSES**

“Nothing to report”

#### **OTHER PRODUCTS**

“Nothing to report”

### **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

#### **INDIVIDUALS WORKING ON THE PROJECT**

<b>Name:</b>	<i>Yoannis Imbert-Fernandez</i>
<b>Project Role:</b>	<i>Principal Investigator</i>
<b>Time Effort:</b>	<i>12 months</i>
<b>Contribution to Project:</b>	<i>Dr. Imbert-Fernandez has conducted all aspects of the research, analyzed the data and prepared a manuscript for publication.</i>

#### **CHANGES TO THE PD/PI AND KEY PERSONNEL**

“Nothing to report”

#### **OTHER ORGANIZATIONS INVOLVED AS PARTNERS**

“Nothing to report”

### **8. SPECIAL REPORTING REQUIREMENTS**

“Not applicable”

### **9. APPENDICES**

#### **Appendix 1.**

Imbert-Fernandez, Y., Clem, B.F., O’Neal, J., Kerr, D.A., Spaulding, R., Lanceta, L., Clem, A.L., Telang, S., Chesney J. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). JBC. 2014 Mar 28;289(13)9440-8. PMID:24515104

**Metabolism:**  
**Estradiol Stimulates Glucose Metabolism  
via 6-Phosphofructo-2-kinase (PFKFB3)**

METABOLISM

Yoannis Imbert-Fernandez, Brian F. Clem,  
Julie O'Neal, Daniel A. Kerr, Robert  
Spaulding, Lilibeth Lanceta, Amy L. Clem,  
Sucheta Telang and Jason Chesney  
*J. Biol. Chem.* 2014, 289:9440-9448.  
doi: 10.1074/jbc.M113.529990 originally published online February 10, 2014

Access the most updated version of this article at doi: [10.1074/jbc.M113.529990](http://dx.doi.org/10.1074/jbc.M113.529990)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](http://www.jbc.org/).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 24 references, 9 of which can be accessed free at  
<http://www.jbc.org/content/289/13/9440.full.html#ref-list-1>

# Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3)\*

Received for publication, October 24, 2013, and in revised form, February 7, 2014. Published, JBC Papers in Press, February 10, 2014, DOI 10.1074/jbc.M113.529990

Yoannis Imbert-Fernandez, Brian F. Clem, Julie O'Neal, Daniel A. Kerr, Robert Spaulding, Lilibeth Lanceta, Amy L. Clem, Sucheta Telang<sup>1</sup>, and Jason Chesney<sup>2</sup>

From the James Graham Brown Cancer Center, Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, Kentucky 40202

**Background:** The regulation of glucose metabolism by estradiol is poorly defined.

**Results:** We find that estradiol stimulates glucose metabolism in part by stimulating the production of fructose 2,6-bisphosphate by PFKFB3.

**Conclusion:** PFKFB3 is a downstream target of estradiol required to stimulate glucose metabolism.

**Significance:** Combined targeting of PFKFB3 and the estrogen receptor may prove beneficial to ER<sup>+</sup> stage IV breast cancer patients.

Estradiol (E2) administered to estrogen receptor-positive (ER<sup>+</sup>) breast cancer patients stimulates glucose uptake by tumors. Importantly, this E2-induced metabolic flare is predictive of the clinical effectiveness of anti-estrogens and, as a result, downstream metabolic regulators of E2 are expected to have utility as targets for the development of anti-breast cancer agents. The family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1–4) control glycolytic flux via their product, fructose-2,6-bisphosphate (F26BP), which activates 6-phosphofructo-1-kinase (PFK-1). We postulated that E2 might promote PFKFB3 expression, resulting in increased F26BP and glucose uptake. We demonstrate that PFKFB3 expression is highest in stage III lymph node metastases relative to normal breast tissues and that exposure of human MCF-7 breast cancer cells to E2 causes a rapid increase in [<sup>14</sup>C]glucose uptake and glycolysis that is coincident with an induction of PFKFB3 mRNA (via ER binding to its promoter), protein expression and the intracellular concentration of its product, F26BP. Importantly, selective inhibition of PFKFB3 expression and activity using siRNA or a PFKFB3 inhibitor markedly reduces the E2-mediated increase in F26BP, [<sup>14</sup>C]glucose uptake, and glycolysis. Furthermore, co-treatment of MCF-7 cells with the PFKFB3 inhibitor and the anti-estrogen ICI 182,780 synergistically induces apoptotic cell death. These findings demonstrate for the first time that the estrogen receptor directly promotes PFKFB3 mRNA transcription which, in turn, is required for the glucose metabolism and survival of breast cancer cells. Importantly, these results provide essential preclinical information that may allow for the ultimate design of combinatorial trials of PFKFB3 antagonists with anti-estrogen therapies in ER<sup>+</sup> stage IV breast cancer patients.

Increased uptake and metabolism of glucose as a source of energy and biosynthetic precursors are common features of primary and metastatic breast adenocarcinomas. As evidence, positron emission tomographic studies with 2-[<sup>18</sup>F]fluoro-2-deoxyglucose (FDG-PET)<sup>3</sup> have consistently demonstrated that human breast tumors display a marked increase in glucose uptake *in vivo* relative to adjacent normal breast tissues (1–5). Consequently, FDG-PET scans have become widely used by medical oncologists to assess the extent of disease and clinical responses to chemotherapies in breast cancer patients. Importantly, objective responses to aromatase inhibitors or ER antagonists in ER<sup>+</sup> breast cancer patients can be predicted by the magnitude of E2-stimulated FDG uptake suggesting that glucose metabolism is an essential clinical target for anti-estrogen therapies (6). Although the stimulation of glucose metabolism by E2 has recently been found to be dependent on the PI3K-AKT pathway (7), relatively little is known about the precise downstream effectors required for E2 to stimulate glucose metabolism in breast cancer cells.

6-Phosphofructo-1-kinase (PFK-1) is the first committed step of glycolysis and a key metabolic sensor of the entire pathway because this enzyme is allosterically inhibited by several products of glucose metabolism including ATP, citrate, and H<sup>+</sup> ions. The most potent activator of PFK-1 is a shunt product of glycolysis, fructose-2,6-bisphosphate (F26BP), which can override the allosteric inhibition by ATP and stimulate PFK-1, glucose uptake, and flux through the entire glycolytic pathway (8, 9). The intracellular concentration of F26BP is maintained by a family of four bifunctional enzymes (PFKFB1–4) with fructose-6-phosphate kinase and F26BP phosphatase activities (10). The PFKFB3 family member is of particular interest because this enzyme (i) has a very high kinase:bisphosphatase ratio, thus overwhelmingly favoring F26BP synthesis and activation of gly-

\* This work was supported, in whole or in part, by NCI/National Institutes of Health Grants 1R01CA140991 (to S. T.) and 1R01CA149438 (to J. C.). This work was also supported by Congressionally Directed Medical Research Program post-doctoral fellowships (to Y. I.-F. and J. O.) and American Cancer Society RSG-10-021-01CNE (to S. T.).

<sup>1</sup> To whom correspondence may be addressed: Dept. of Medicine, James Graham Brown Cancer Center, University of Louisville, 505 S. Hancock St., Louisville, KY 40202. Tel.: 502-852-3687; E-mail: sucheta.telang@louisville.edu.

<sup>2</sup> To whom correspondence may be addressed: Dept. of Medicine, James Graham Brown Cancer Center, University of Louisville, 505 S. Hancock St., Louisville, KY 40202. Tel.: 502-852-3679; E-mail: jason.chesney@louisville.edu.

<sup>3</sup> The abbreviations used are: FDG-PET, positron emission tomographic studies with 2-[<sup>18</sup>F]fluoro-2-deoxyglucose; 2-[<sup>14</sup>C]DG, 2-[<sup>14</sup>C]-deoxy-D-glucose; E2, estradiol; ER, estrogen receptor; ERE, estrogen receptor response element; F26BP, fructose-2,6-bisphosphate; Fru-6-P, fructose 6-phosphate; Glu-6-P, glucose 6-phosphate; PFK, 1–6-phosphofructo-1-kinase; PFKFB, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase; PI, propidium iodide.

colysis; and (ii) is overexpressed in breast tumors relative to normal mammary epithelial cells *in situ* (10–12).

Although the precise mechanisms for increased PFKFB3 expression in breast cancers are not well understood, PFKFB3 mRNA transcription is promoted by hypoxia inducible factor-1 $\alpha$  (13, 14) and by the progesterone receptor (15). Additionally, loss of the tumor suppressor *PTEN* has recently been found to reduce APC/Cdh1-mediated degradation of PFKFB3 (16). The observation that the *PFKFB3* promoter contains putative ER response elements (ERE) (14) prompted us to determine whether PFKFB3 is a direct transcriptional target of ER. Considering previous research showing that E2 increases glucose uptake *in vivo* and *in vitro* (6, 7), together with the glycolysis-activating function of PFKFB3, we postulated that PFKFB3 may be a downstream effector of E2 that serves to activate the energetic and anabolic pathways required for the survival and growth of breast cancer cells.


## EXPERIMENTAL PROCEDURES

**Chemicals**—E2, cycloheximide, and actinomycin D were purchased from Sigma-Aldrich. ICI 182,780 (Fulvestrant) was purchased from Tocris. PFK158 was provided by Advanced Cancer Therapeutics. The compound consists of (*E*)-1-(pyridin-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one.

**Antibodies and Western Blotting**—Antibodies against PFKFB3 and  $\beta$ -actin were purchased from Proteintech and Sigma-Aldrich, respectively. Whole cell lysates were harvested using Pierce lysis buffer supplemented with protease inhibitors. Protein concentration was determined by the BCA method (Pierce). Proteins were separated on 10% Mini PROTEAN TGX gels (Bio-Rad) and transferred to PVDF membranes (Millipore). The membranes were blocked with 5% nonfat milk in TBS-T (0.1% Tween 20) and immunoblotted with the indicated antibodies. Amersham Biosciences ECL Western blotting detection reagent (GE Healthcare) was used to detect protein bands. The membranes were visualized on Biomax ML film (Kodak).

**Cell Culture**—MCF-7 and T-47D cells were purchased from American Type Culture Collection (ATCC). MCF-7 cells were maintained in Improved Minimum Essential Medium supplemented with 10% fetal bovine serum (FBS) and Pen-Strep (Invitrogen). T-47D cells were maintained in RPMI 1640 medium supplemented with 10% FBS and 0.2 unit/ml bovine insulin. Cells were serum-starved (5% dextran-coated charcoal-stripped FBS) in phenol red-free media for 72 h prior to E2 treatments.

**RNA Extraction and Real-time Quantitative RT-PCR**—Total RNA was extracted using RNeasy spin columns (Qiagen). Reverse transcription was performed by using random primers and the High Capacity cDNA Archive Kit (Applied Biosystems). Quantitative RT-PCR was performed with the ABI PRISM 7500 using TaqMan primers and probes for PFKFB3 and control gene  $\beta$ -actin purchased as Assays-on-Demand™ Gene Expression Products (Applied Biosystems). Analysis and -fold differences were determined using the comparative  $C_T$  method. Unless otherwise indicated, -fold change was calculated from the  $\Delta\Delta C_T$  values with the formula  $2^{-\Delta\Delta C_T}$ . Experiments were repeated at least three times.




**FIGURE 1. High expression of PFKFB3 by metastatic breast adenocarcinoma cells in lymph nodes.** A, four normal breast tissues, stage II primary breast adenocarcinomas, and stage III lymph node metastases were analyzed for PFKFB3 expression using immunohistochemistry. B, digital immunohistochemical image analysis was performed, and the ratio of positive pixels to total pixels was quantified for each of the tissue specimens. *p* values comparing normal mammary tissues with stage II and stage III lymph node metastases and between stage II and III lymph node metastases are included in the figure.

**Immunohistochemistry**—Five- $\mu$ m sections of formalin-fixed and paraffin-embedded tumor tissue were mounted on charged glass slides and dried at 58 °C for 60 min. Slides were first deparaffinized with xylene, and then epitope retrieval was carried out using citrate buffer in a 2100 Retriever (PickCell Laboratories). The sections were blocked with 10% goat serum for 1 h, then incubated with primary antibody (anti-PFKFB3 1:50; Proteintech) overnight, followed by an HRP-linked goat anti-rabbit secondary antibody (1:300; Pierce). The sections were developed with 3,3'-diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories) for 2 min, and nuclei were counterstained with hematoxylin (Sigma-Aldrich) for 2 min. PBS washes were performed between all steps. The slides were dehydrated in graded alcohols (100, 95, and 80% ethanol (v/v) in H<sub>2</sub>O) and cleared in xylene, and coverslips were attached with Permount (Fisher Scientific). Slides were scanned using a ScanScope XT Digital Slide Scanner (Aperio) and data analyzed with the positive pixel count algorithm (ImageScope; Aperio).

**Chromatin Immunoprecipitation (ChIP) Assay**—ChIP experiments were performed using the simpleChIP kit (Cell Signaling) and following the manufacture's instructions. In brief, 10<sup>7</sup> MCF-7 cells/immunoprecipitation were treated with vehicle control EtOH or 10 nM E2 for 1 h. Chromatin was cross-linked by incubating the cells with 1% formaldehyde for 10 min. Immunoprecipitation of the lysed extracts was performed using





**FIGURE 2. Regulation of PFKFB3, F26BP, glucose uptake, and glycolysis by E2 in MCF-7 cells.** MCF-7 cells were stimulated with 10 nM and 100 nM E2 for the indicated times and analyzed for PFKFB3 mRNA by real-time PCR (A), PFKFB3 protein expression by Western blot analysis and densitometry (C and D), F26BP using an enzyme-coupled reaction dependent on NADH oxidation (B), 2-[<sup>14</sup>C]DG uptake (E) and glycolysis as measured by the release of <sup>3</sup>H<sub>2</sub>O by enolase (F). Values are the mean ± S.E. (error bars) of three experiments; \*, *p* < 0.01.

the following ChIP grade antibodies: anti-ERα (HC-20), anti-ERβ (H-150) from Santa Cruz Biotechnology, or normal rabbit IgG (Cell Signaling). The primers used for PCR of the PFKFB3 promoter region containing an ERE were: (−2023 to −2198), CGCGTTATTGACAGACAGGA (FWD)/AGCTCACAGGGAGAGCAGAG (REV), and (−2982 to −3308), CTCCTGAGCTCAAGCAATCC (FWD)/GGGTGCTGAGTGGAAATCCTA (REV). As a positive control, primers flanking the established ERE in the human pS2 (trefoil factor 1 (*TFF1*)) gene promoter were used (17). Primers to a distal region (−9196 to −9432), AGTTGAATCGCTGCAAAGGT (FWD)/ACCCAGGTGAAATCAACAGC (REV) of the PFKFB3 promoter were used as a negative control.

**Measurement of F26BP**—MCF-7 cells were treated with EtOH vehicle control, 10 or 100 nM E2 for the indicated times. Cells were washed in PBS and lysed in NaOH/Tris acetate by heating at 80 °C for 5 min. Lysates were neutralized to pH 7.2 by adding ice-cold acetic acid and HEPES. F26BP concentration was determined using the method described by Van Schaftingen *et al.* (9).

**Glucose Uptake**—MCF-7 cells were treated with EtOH vehicle control, 10 or 100 nM E2 for the indicated time periods and

subsequently placed in glucose-free RPMI 1640 medium for 30 min. 2-[<sup>14</sup>C]Deoxyglucose (0.25 μCi/ml; PerkinElmer Life Sciences) was added for an additional 15 min, and cells were then washed three times with ice-cold RPMI 1640 medium containing no glucose. Cell lysates were collected in 500 μl of 0.1% SDS, and scintillation counts (counts/min) were measured using 350 μl of lysate. Protein concentration was determined using the BCA assay according to the manufacturer's instructions and measured on a Powerwave XS plate reader (Biotek). Counts were normalized to protein concentration.

**Glycolysis Assay**—MCF-7 cells growing in 6-well plates were incubated in 500 μl of complete medium containing 1 μCi of 5-[<sup>3</sup>H]glucose for 60 min in 5% CO<sub>2</sub> at 37 °C. The medium was then collected and centrifuged for 5 min at 8000 rpm to pellet any cells. To separate the <sup>3</sup>H<sub>2</sub>O formed via glycolysis from the 5-[<sup>3</sup>H]glucose added to the medium, an evaporation technique in a sealed system was utilized. Briefly, 150 μl of medium aliquots were added in open tubes that were placed upright inside scintillation vials containing 1 ml of H<sub>2</sub>O. The scintillation vials were sealed, and the <sup>3</sup>H<sub>2</sub>O produced by glycolysis through enolase and released to the medium was allowed to equilibrate with the H<sub>2</sub>O in the outer vial for 48 h at 37 °C. The amounts of <sup>3</sup>H<sub>2</sub>O

that had diffused into the surrounding  $H_2O$  was measured on a Tri-Carb 2910 liquid scintillation analyzer (PerkinElmer Life Sciences) and compared with  $^3H_2O$  and 5- $[^3H]$ glucose standards. Protein concentration was determined using the BCA assay according to the manufacturer's instructions and measured on a Powerwave XS plate reader. Counts were normalized to protein concentration.

**Transfection and siRNA**—Cells were seeded in 6-well plates at a density of  $1 \times 10^5$  cells/well. Cells were transfected with control siRNA or PFKFB3 siRNA (Invitrogen) using Lipofectamine RNAiMAX reagent (Invitrogen) and allowed to incubate for 48 h prior to E2 treatment.


**PFKFB3 Adenovirus Expression**—pAdenoG-HA (vector) and PFKFB3-HA adenovirus (human) were purchased from Applied Biological Materials. For infection experiments, MCF-7 cells were seeded in 6-well plates at a density of  $1 \times 10^5$  cells/well and allowed to attach overnight. The cells were then placed in 1 ml of medium containing  $1 \times 10^6$  viral particles and allowed to incubate for 48 h.

**Annexin V/Propidium Iodide (PI) Staining**—MCF-7 cells were seeded in 6-well plates at a density of  $1 \times 10^5$  cells/well and starved for 72 h prior to treatment. Cells were incubated with 10 nM E2 and dimethyl sulfoxide, 100 nM ICI 182,780, 5  $\mu$ M PFK158 or the combination of ICI 182,780 and PFK158 for 24 h. Cells were washed with PBS and stained with Annexin V and PI (BD Pharmingen). Fluorescence was measured using a FACSCalibur (BD Biosciences) and analyzed using FloJo (Tree Star). Annexin V<sup>−</sup>/PI<sup>−</sup> (live) and Annexin V<sup>+</sup>/PI<sup>+</sup> (late apoptotic) cells were quantified by the frequency of fluorescently labeled cells, and statistical significance was assessed by the two-sample *t* test (independent variable).

## RESULTS


**High PFKFB3 Protein Expression in Lymph Node Metastases**—Previously, PFKFB3 expression was found to be elevated in primary breast adenocarcinomas (12). We confirmed high PFKFB3 expression in stage II breast adenocarcinomas relative to normal breast tissues using immunohistochemical analyses (Fig. 1A). We also examined the metastatic breast adenocarcinoma cells in lymph nodes resected from patients suffering from stage III breast cancer and observed an incremental increase in PFKFB3 protein expression (Fig. 1A). This increase in PFKFB3 expression in stage II and lymph node metastases then was statistically confirmed using digital immunohistochemical image analysis (Fig. 1B).

**PFKFB3 Expression, F26BP, Glucose Uptake, and Glycolysis Are Induced by E2 in MCF-7 Cells**—Given that E2 increases the glucose uptake of ER<sup>+</sup> breast cancer cells *in vitro* and *in vivo* (6, 7) and that the PFKFB3 promoter has putative EREs (14), we postulated that ER and its ligand, E2, might regulate PFKFB3 mRNA expression. Initially, we examined PFKFB3 mRNA expression by real-time RT-PCR after exposure to EtOH (vehicle control), or 10 or 100 nM E2 for 1, 3, 6, and 24 h. We observed a marked increase in PFKFB3 mRNA levels after only 1 h of exposure to either 10 or 100 nM E2 (Fig. 2A). PFKFB3 mRNA returned to near basal levels after 3 and 6 h of incubation with E2 but was still statistically increased relative to the vehicle control (Fig. 2A). Importantly, co-culture with the anti-estro-



**FIGURE 3. E2 causes ERα recruitment to the PFKFB3 promoter.** A, ChIP assay experiments were performed with MCF-7 cells treated with EtOH or 10 nM E2 for 1 h using antibodies to ERα (HC20) or ERβ (H150) or with rabbit preimmune serum (IgG) and primers flanking the −2000, −3000, and distal regions (lacking ERE sites) of the PFKFB3 promoter. Real-time PCR fold results were normalized to input and are shown as fold enrichment over IgG immunoprecipitation in EtOH-treated cells from three independent ChIP experiments. B, representative 2% agarose gel using similar conditions and primers is also shown. \*, *p* < 0.01 compared with vehicle control.

gen ICI 182,780 (ICI; 100 nM) blocked the induction of PFKFB3 mRNA indicating that the ER is required for the up-regulation of PFKFB3 mRNA expression (Fig. 2A). In addition, pretreatment of MCF-7 cells with the transcription inhibitor actinomycin D, suppressed the increase in PFKFB3 mRNA indicating that new mRNA synthesis is required whereas pretreatment with the protein synthesis inhibitor cycloheximide, had no effect (Fig. 2A). We next examined endogenous PFKFB3 protein expression in response to E2 and found that PFKFB3 protein significantly increased after 3 h and 6 h of exposure to 10 or 100 nM E2 but returned to baseline after 24 h (Fig. 2, C and D). Similar to PFKFB3 protein, the steady-state concentration of its product, F26BP, significantly increased after 3 h and 6 h of exposure to 10 and 100 nM E2 (Fig. 2B). To then monitor the effect of E2 on glucose uptake, MCF-7 cells were placed in phenol red-free medium supplemented with 5% dextran-coated charcoal-stripped serum for 72 h prior to the addition of E2 and 2-[1- $^{14}C$ ]deoxy-D-glucose (2-[ $^{14}C$ ]DG). We observed a time-dependent increase in glucose uptake in MCF-7 cells exposed to 10 and 100 nM E2 for 3–24 h (Fig. 2E). We next examined glycolysis by measuring the release of  $^3H_2O$  from 5- $[^3H]$ glucose via enolase which is downstream of PFK-1 in the glycolytic



**FIGURE 4. PFKFB3 is required for E2-induced glucose uptake and glycolysis.** MCF-7 cells were transfected with PFKFB3 siRNA and allowed to incubate for 48 h prior to stimulation with 10 nM E2. Shown are PFKFB3 protein expression by Western blot analysis after 3-h stimulation with E2 (A), densitometry analysis of relative PFKFB3/ $\beta$ -actin (B), F26BP concentration (C), [ $^{14}$ C]DG uptake (D), and glycolysis as measured by the release of  $^3$ H $_2$ O by enolase (E). Values represent three independent experiments. \*,  $p < 0.01$  relative to control siRNA.

pathway. We found that E2 also caused a marked increase in glycolysis by MCF-7 cells that coincided with the observed increase in glucose uptake (Fig. 2F). Given that the F26BP concentration returns to near baseline 6 h after stimulation by E2, we suspect that the maintenance of increased glucose metabolism observed at 24 h is mediated by secondary events that regulate glucose transporters and/or glycolytic enzymes. Importantly, we did not observe an increase in the mRNA expression of several key control steps in glycolysis including GLUT1–4, hexokinase, PFK-1, and pyruvate kinase at 24 h (data not shown). We also assessed PFKFB3 expression after 10 nM E2 exposure in a second ER $^{+}$  breast cancer cell line (T-47D) and found that PFKFB3 mRNA and protein were increased 3.9-fold (1 h) and 3.0-fold (3 h), respectively (data not shown).

**ER $\alpha$  Is Recruited to the PFKFB3 Gene upon E2 Stimulation—**We next analyzed the 5' PFKFB3 promoter sequence using the TRANSFAC software (Biobase) to identify putative transcription factors binding sites, including the ER. Our analysis revealed four putative half-site ERE sites located around the –2000 and –3000 regions along with several SP1 sites. To investigate whether the E2-induced increase in PFKFB3 mRNA involves recruitment of the ER to the PFKFB3 promoter we performed ChIP assays using primers that could amplify the –2000, –3000, and a distal region of the PFKFB3 promoter. We used antibodies against ER $\alpha$  and ER $\beta$  to immunoprecipitate

the chromatin collected from MCF-7 cells treated with 10 nM E2 for 1 h and then performed real-time quantitative PCR to determine recruitment to the PFKFB3 promoter. Our results demonstrate a 4-fold enrichment in the recruitment of the ER $\alpha$  to the –2000 region of the PFKFB3 promoter after 1 h of E2 exposure (Fig. 3A (real-time PCR) and Fig. 3B (2% agarose gel as a representative example)). We did not observe a significant recruitment of the ER $\alpha$  to the –3000 region or a distal region of the PFKFB3 gene which is devoid of putative EREs. We also observed no recruitment of the ER $\beta$  to the PFKFB3 gene and found that primers recognizing the pS2 promoter, a previously described ER $\alpha$  target (18), amplified the pS2 promoter sequence as a positive control. In summary, these studies demonstrate that stimulation of MCF-7 cells with 10 nM E2 for 1 h causes an increase in ER $\alpha$  recruitment to the PFKFB3 promoter.

**E2 Increases Glucose Uptake and Glycolysis via PFKFB3 in MCF-7 Cells—**To determine whether the stimulation of glucose uptake by E2 requires PFKFB3 expression, we next analyzed E2-stimulated glucose uptake by MCF-7 cells transfected with a control or PFKFB3-specific siRNA. Briefly, MCF-7 cells were transiently transfected with either control siRNA or PFKFB3 siRNA, and, 48 h later the cells were exposed to vehicle or the physiologically relevant 10 nM E2 for 3 h followed by incubation with 2-[1- $^{14}$ C]DG. We confirmed that PFKFB3 pro-






FIGURE 5. **PFK158 inhibits E2-induced glucose uptake and glycolysis.** MCF-7 cells were simultaneously stimulated with E2 and exposed to 3  $\mu\text{M}$  PFK158 for 3 h and then analyzed for PFKFB3 protein expression (A), densitometry analysis of relative PFKFB3/ $\beta$ -actin (B), F26BP (C), 2-[ $^{14}$ C]DG uptake (D), and glycolysis as measured by the release of  $^3\text{H}_2\text{O}$  by enolase (E). Values represent three independent experiments. \*,  $p < 0.001$  relative to vehicle.

tein expression was decreased by transfection with PFKFB3 siRNA relative to the control siRNA and found that the PFKFB3 siRNA completely blocked the E2-mediated up-regulation of PFKFB3 expression (Fig. 4, A and B). PFKFB3 has the highest kinase:bisphosphatase ratio of the PFKFB family, and we postulated that inhibition of PFKFB3 expression would suppress the intracellular F26BP concentration. We found that transfection with the PFKFB3 siRNA (which does not affect the other family members) markedly reduced the F26BP concentration in vehicle- and E2-stimulated MCF-7 cells after 3 h (Fig. 4C). To test the hypothesis that PFKFB3/F26BP is required for the stimulation of glucose uptake and glycolysis by E2, we examined the effect of PFKFB3 siRNA on the 2-[ $^{14}$ C]DG uptake and  $^3\text{H}_2\text{O}$  release (*i.e.* glycolysis) stimulated by E2. We found that transfection with the PFKFB3 siRNA reduced basal glucose uptake and glycolysis and completely blocked the stimulation of glucose uptake and glycolysis caused by E2 at 3 h (Fig. 4, D and E). Taken together, these data indicate that E2 rapidly stimulates glucose uptake in part by increasing PFKFB3 expression and F26BP.

**A Small Molecule Inhibitor of PFKFB3 Blocks the E2-mediated Increase in Glucose Uptake and Glycolysis in MCF-7 Cells**—We next postulated that inhibition of the kinase activity of PFKFB3 by a clinical-grade PFKFB3 inhibitor, PFK158, would, like the PFKFB3 siRNA, attenuate the E2-mediated stimulation of F26BP and glucose uptake and glycolysis. Ini-

tially, we identified a concentration of PFK158 that does not affect viability after 3 h of exposure (3  $\mu\text{M}$ ; data not shown). We then examined the effect of PFK158 on PFKFB3 protein expression in the absence and presence of 10 nM E2 and observed relatively little effect on the E2-induced expression of PFKFB3 (Fig. 5, A and B). However, we did observe a marked decrease in the E2-stimulated F26BP (Fig. 5C), 2-[ $^{14}$ C]DG uptake (Fig. 5D) and glycolysis (Fig. 5E). These data indicate that selective inhibition of the substrate-binding domain of PFKFB3 is sufficient to completely block the ability of E2 to stimulate glucose uptake. Of note, whereas transfection of unstimulated MCF-7 cells with the PFKFB3 siRNA significantly reduced glucose uptake and glycolysis (Fig. 4, D and E), exposure of unstimulated MCF-7 cells to PFK158 did not reduce glucose uptake or glycolysis (Fig. 5D, 5E). We believe that this disparity may be because of the relative potency of PFK158 which competitively but not completely inhibits PFKFB3 (unlike the PFKFB3 siRNA which essentially depletes all PFKFB3 protein).

**Forced Expression of PFKFB3 Increases F26BP, Glucose Uptake, and Glycolysis in MCF-7 Cells**—Given that both PFKFB3 siRNA and PFK158 can suppress the E2-stimulated increase in F26BP, glucose uptake, and glycolysis, we sought to determine whether PFKFB3 expression by itself would result in similar biochemical changes. We transiently expressed PFKFB3 in MCF-7 cells and found that forced expression of PFKFB3




FIGURE 6. **Forced expression of PFKFB3 increases glucose uptake and glycolysis.** MCF-7 cells were transduced with adenovirus-encoded PFKFB3 and then analyzed for PFKFB3 mRNA (A), F26BP (B), PFKFB3 protein expression (C), densitometry analysis of relative PFKFB3/ $\beta$ -actin (D), 2-[ $^{14}$ C]DG uptake (E), and glycolysis as measured by the release of  $^3\text{H}_2\text{O}$  by enolase (F). Values represent three independent experiments. \*,  $p < 0.001$  relative to vehicle.

mRNA (Fig. 6A) and protein (Fig. 6, C and D) can increase the steady-state concentration of F26BP (Fig. 6B), glucose uptake (Fig. 6E), and glycolysis (Fig. 6F) in MCF-7 cells.

**Effect of ICI 182,780 on PFK158-induced Apoptotic Death—**To determine the utility of combining anti-estrogens with PFKFB3 inhibitors, we next examined the effects of 100 nM ICI 182,780, a commonly prescribed pure anti-estrogen compound, a pro-apoptotic concentration of PFK158 (5  $\mu\text{M}$  at 24 h), or combined 100 nM ICI 182,780 + 5  $\mu\text{M}$  PFK158 on apoptosis using Annexin V/PI staining by flow cytometry. We observed that the addition of ICI 182,780 caused a synergistic increase in late apoptotic MCF-7 cells relative to that caused by PFK158 alone after 24 h of exposure (Fig. 7, A and B). These data suggest that the addition of PFK158 to anti-estrogen therapeutic agents may increase response rates and perhaps the durability of responses in preclinical and clinical studies.


## DISCUSSION

In this study, we describe PFKFB3 as an early molecular target of estradiol via direct binding of the ER to the *PFKFB3* promoter. We also show that E2 up-regulates PFKFB3 expression in ER-responsive MCF-7 cells, increasing the steady-state concentration of F26BP, glucose uptake, and glycolysis. Although our study does not characterize all of the potential mechanisms by which E2 increases glucose metabolism, our results do demonstrate that PFKFB3 expression and activity are required to

mediate E2-mediated glucose uptake and glycolysis. We postulate that the increase in F26BP by E2 leads to the stimulation of PFK-1 which, in turn, may cause a reduction in the PFK-1 substrate Fru-6-P, which is in equilibrium with Glc-6-P, an allosteric inhibitor of hexokinase, which itself is required for glucose uptake (19–21). Importantly, the ability of PFKFB3 to regulate glucose uptake has been demonstrated previously by work showing that genetic ablation of the *pfkfb3* gene reduces F26BP and glucose uptake in transformed cells *in vivo* and *in vitro* (22).

The therapeutic implications of our observation that E2 requires PFKFB3 to stimulate glucose metabolism *in vitro* are 2-fold: (i) F26BP may be required for the metabolic flare induced by E2 in breast cancer patients; and (ii) combined inhibition of PFKFB3 and ER functions may be an effective therapeutic strategy for ER<sup>+</sup> stage IV breast cancer patients.


The activation of the ER by estrogens serves a critical role in cancer initiation and progression, and their antagonists have proven efficacy in the treatment of breast cancers. Anti-estrogen therapies include selective ER modulators such as Tamoxifen that act as partial receptor agonists, estrogen synthesis inhibitors such as aromatase inhibitors, and receptor expression inhibitors such as the anti-estrogen ICI 182,780. Each of these modalities is effective in 50–70% of breast cancer patients initially, but recurrent ER<sup>+</sup> breast tumors respond to such anti-estrogen treatments in only ~30% of patients, and durable



**FIGURE 7. Synergistic pro-apoptotic effect of combined treatment with ICI 182,780/PFK158.** A, MCF-7 cells were exposed to 100 nM ICI 182,780, 5  $\mu$ M PFK158, or both agents for 24 h and analyzed for Annexin V/PI staining by flow cytometry. B, absolute cell numbers for double negative and double positive cells were quantified.

responses are even rarer (23). Consequently, there is an important need to identify novel ER signaling targets, such as PFKFB3, to guide the development of therapeutic strategies to maximize endocrine responses.

Our observation that E2 increases PFKFB3 expression and F26BP synthesis is the first report that ER signaling regulates PFKFB3 expression and activity. PFKFB3 is a key regulator of glucose metabolism and has proven to be an important target for antineoplastic therapy (24). Additionally, PFKFB3 ChIP experiments demonstrate interaction of the ER $\alpha$  at the half-site EREs located on the  $-2000$  region of the PFKFB3 promoter. Based on these results, we envision the following series of events mediated by exposure of ER<sup>+</sup> breast cancer cells to E2: (i) E2 increases PFKFB3 transcription by a mechanism involving ER $\alpha$  occupancy of the PFKFB3 promoter; (ii) the increase in



**FIGURE 8. Model of the regulation of PFKFB3 by E2.** In this schematic, we summarize our model whereby E2 binds and activates ER, translocates to the nucleus, and promotes PFKFB3 mRNA transcription. Translated PFKFB3 produces F26BP which allosterically activates PFK-1 and stimulates glucose uptake and the entire glycolytic pathway.

PFKFB3 mRNA translates into an increase in protein and more importantly, an increase in the product, F26BP; and (iii) F26BP activates PFK-1, an essential control enzyme for the entire glycolytic pathway, which reduces Fru-6-P and Glc-6-P, resulting in less allosteric inhibition of hexokinase and increased glucose uptake (Fig. 8).

## CONCLUSIONS

In this study we have found that PFKFB3 and its product, F26BP, are induced by E2 and required for the E2-mediated stimulation of glucose uptake and glycolysis. We also have found that a PFKFB3 inhibitor undergoing phase I trial testing in solid tumor patients, PFK158, causes a synergistic increase in apoptosis by ER<sup>+</sup> breast cancer cells when combined with the widely used anti-estrogen ICI 182,780. These observations support the conduct of Investigational New Drug-enabling preclinical toxicity and efficacy studies of combinations of PFK158 and ICI 182,780 to facilitate the eventual development of phase I/II trials in ER<sup>+</sup> stage IV breast cancer patients.

**Acknowledgments**—We thank Drs. John Eaton and Otto Grubraw for assisting with the interpretation of our data.

## REFERENCES

- Constantinidou, A., Martin, A., Sharma, B., and Johnston, S. R. (2011) Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. *Ann. Oncol.* **22**, 307–314
- Martoni, A. A., Zamagni, C., Quercia, S., Rosati, M., Cacciari, N., Bernardi, A., Musto, A., Fanti, S., Santini, D., and Taffurelli, M. (2010) Early <sup>18</sup>F-2-fluoro-2-deoxy-D-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. *Cancer* **116**, 805–813
- Niikura, N., and Ueno, N. T. (2010) The role of F-FDG-positron emission tomography/computed tomography in staging primary breast cancer. *J. Cancer* **1**, 51–53
- Pennant, M., Takwoingi, Y., Pennant, L., Davenport, C., Fry-Smith, A.,

- Eisinga, A., Andronis, L., Arvanitis, T., Deeks, J., and Hyde, C. (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. *Health Technol. Assess.* **14**, 1–103
5. Specht, J. M., Kurland, B. F., Montgomery, S. K., Dunnwald, L. K., Doot, R. K., Gralow, J. R., Ellis, G. K., Linden, H. M., Livingston, R. B., Allison, K. H., Schubert, E. K., and Mankoff, D. A. (2010) Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. *Clin. Cancer Res.* **16**, 2803–2810
6. Dehdashti, F., Mortimer, J. E., Trinkaus, K., Naughton, M. J., Ellis, M., Katzenellenbogen, J. A., Welch, M. J., and Siegel, B. A. (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. *Breast Cancer Res. Treat.* **113**, 509–517
7. Ko, B. H., Paik, J. Y., Jung, K. H., and Lee, K. H. (2010) 17 $\beta$ -Estradiol augments <sup>18</sup>F-FDG uptake and glycolysis of T-47D breast cancer cells via membrane-initiated rapid PI3K-AKT activation. *J. Nucl. Med.* **51**, 1740–1747
8. Van Schaftingen, E., Hue, L., and Hers, H. G. (1980) Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. *Biochem. J.* **192**, 897–901
9. Van Schaftingen, E., Hue, L., and Hers, H. G. (1980) Control of the fructose-6-phosphate/fructose 1,6-bisphosphate cycle in isolated hepatocytes by glucose and glucagon: role of a low-molecular-weight stimulator of phosphofructokinase. *Biochem. J.* **192**, 887–895
10. Yalcin, A., Telang, S., Clem, B., and Chesney, J. (2009) Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. *Exp. Mol. Pathol.* **86**, 174–179
11. Sakakibara, R., Kato, M., Okamura, N., Nakagawa, T., Komada, Y., Tomi-naga, N., Shimojo, M., and Fukasawa, M. (1997) Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. *J. Biochem.* **122**, 122–128
12. Atsumi, T., Chesney, J., Metz, C., Leng, L., Donnelly, S., Makita, Z., Mitchell, R., and Bucala, R. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. *Cancer Res.* **62**, 5881–5887
13. Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., and Caro, J. (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene: its possible role in the Warburg effect. *J. Biol. Chem.* **277**, 6183–6187
14. Obach, M., Navarro-Sabaté, A., Caro, J., Kong, X., Duran, J., Gómez, M., Perales, J. C., Ventura, F., Rosa, J. L., and Bartrons, R. (2004) 6-Phosphofructo-2-kinase (*pfkfb3*) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. *J. Biol. Chem.* **279**, 53562–53570
15. Novellademunt, L., Obach, M., Millán-Arino, L., Manzano, A., Ventura, F., Rosa, J. L., Jordan, A., Navarro-Sabate, A., and Bartrons, R. (2012) Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells. *Biochem. J.* **442**, 345–356
16. Garcia-Cao, L., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C., Anastasiou, D., Ito, K., Sasaki, A. T., Rameh, L., Carracedo, A., Vander Heiden, M. G., Cantley, L. C., Pinton, P., Haigis, M. C., and Pandolfi, P. P. (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. *Cell* **149**, 49–62
17. Bourdeau, V., Deschênes, J., Métivier, R., Nagai, Y., Nguyen, D., Bretschneider, N., Gannon, F., White, J. H., and Mader, S. (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. *Mol. Endocrinol.* **18**, 1411–1427
18. Liu, X. F., and Bagchi, M. K. (2004) Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters *in vivo*. *J. Biol. Chem.* **279**, 15050–15058
19. Gregoriou, M., Cornish-Bowden, A., and Trayer, I. P. (1981) Isotope-exchange evidence for allosteric regulation of hexokinase II by glucose 6-phosphate and for an obligatory addition of substrates. *Biochem. Soc. Trans.* **9**, 62–63
20. Gregoriou, M., Trayer, I. P., and Cornish-Bowden, A. (1983) Isotope-exchange evidence that glucose 6-phosphate inhibits rat-muscle hexokinase II at an allosteric site. *Eur. J. Biochem.* **134**, 283–288
21. Lazo, P. A., and Bosca, L. (1982) Mitochondrial membrane-bound hexokinase of ascites tumor cells. Functional implications of lysine residues studied by modification with imidoesters. *Hoppe Seylers Z. Physiol. Chem.* **363**, 635–641
22. Telang, S., Yalcin, A., Clem, A. L., Bucala, R., Lane, A. N., Eaton, J. W., and Chesney, J. (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. *Oncogene* **25**, 7225–7234
23. Ingle, J. N. (2013) Pharmacogenomics of endocrine therapy in breast cancer. *J. Hum. Genet.* **58**, 306–312
24. Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., 2nd, Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., Telang, S., and Chesney, J. (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. *Mol. Cancer Ther.* **12**, 1461–1470